{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053902","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2026-08-06T12:10:00+00:00","discovered_at":"2026-08-06T12:15:00.361373+00:00","generated_at":"2026-08-06T12:15:32.734662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Delcath Q2 revenue $29.1M, up 20% YoY; raises FY 2026 revenue guidance to $104-108M","bullets":["Total revenue $29.1M (Q2 2026) vs $24.2M (Q2 2025); HEPZATO KIT $27.1M, CHEMOSAT $2.0M.","Net income $2.7M (flat YoY); non-GAAP adjusted EBITDA $7.6M vs $9.8M prior year.","Cash and investments $95.9M, no debt as of June 30, 2026.","FY 2026 revenue guidance raised to $104-108M (≥28% HEPZATO volume growth); gross margins 86-89%.","31 active treatment centers; HEPZATO volume grew ~30% YoY in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053902","json":"https://secwatch.observer/filing/0001628280-26-053902.json","markdown":"https://secwatch.observer/filing/0001628280-26-053902.md","text":"https://secwatch.observer/filing/0001628280-26-053902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828026053902/0001628280-26-053902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828026053902/dcth-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:15:32.734662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}